Tags : Navrogen

PharmaShots Weekly Snapshot (February 03-07, 2020)

Tuba Khan February 10, 2020

WHO to Accelerate Global Research and Innovation Against Corona Virus Published: Feb 06, 2020 | Tags: WHO, Accelerate, Global, Research, Innovation, Against, Corona Virus 2. Curis Amends its Existing Collaboration […]readmore

Biotech

Navrogen and Levena Collaborate to Develop ADCs for Humoral Immuno-Suppressed

Tuba Khan February 5, 2020

Shots: Navrogen expands its collaboration with Levena to develop ADCs targeting humoral immuno-suppressed cancers The collaboration will deploy Levena’s linker and cytotoxic payload chemistry expertise with Navrogen’s cancer-targeting Abs discovered […]readmore

Tags : Navrogen

PharmaShots Weekly Snapshot (February 03-07, 2020)

Navrogen and Levena Collaborate to Develop ADCs for Humoral Immuno-Suppressed

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Navrogen

PharmaShots Weekly Snapshot (February 03-07, 2020)

Navrogen and Levena Collaborate to Develop ADCs for Humoral Immuno-Suppressed

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company